Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Carden Jennings Publishing Country of Publication: United States NLM ID: 9600628 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6536 (Electronic) Linking ISSN: 10838791 NLM ISO Abbreviation: Biol Blood Marrow Transplant Subsets: MEDLINE
    • Publication Information:
      Publication: Charlottesville, VA : Carden Jennings Publishing
      Original Publication: Charlottesville, VA : Kluge Carden Jennings Publishing, Co., Ltd., [1995-
    • Subject Terms:
      Comorbidity* ; Prognosis*; Allografts/*standards ; Hematopoietic Stem Cell Transplantation/*methods ; Leukemia, Myeloid, Acute/*therapy ; Myelodysplastic Syndromes/*therapy; Adolescent ; Adult ; Aged ; Antigens, CD34/analysis ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Middle Aged ; Models, Theoretical ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/mortality ; Retrospective Studies ; Survival Analysis ; Transplantation, Homologous ; Young Adult
    • Abstract:
      To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a homogeneous population of patients undergoing allogeneic HCT with CD34-selected grafts for acute myeloid leukemia and myelodysplastic syndrome (n = 346). Median HCT-CI and HCT-CI/age scores were 2 (percentile 25 to 75, 1 to 4) and 3 (percentile 25 to 75, 1 to 5), respectively. Higher HCT-CI and HCT-CI/age scores were associated with higher nonrelapse mortality (NRM) and lower overall survival (OS). The HCT-CI distinguished 2 risk groups (0 to 2 versus ≥3), whereas, with the HCT-CI/age, there was a progressive increase in NRM and decrease in OS with increasing scores in all 4 groups (0 versus 1 to 2 versus 3 to 4 versus ≥5). Higher scores in both models were associated with lower chronic graft-versus-host disease relapse-free survival but not with higher relapse. Both models showed a promising predictive accuracy for NRM (c- = .616 for HCT-CI and c- = .647 for HCT-CI/age). In conclusion, the HCT-CI and HCT-CI/age predict transplant outcomes in CD34-selected allo-HCT, including NRM, OS, and chronic graft-versus-host disease relapse-free survival and may be used to select appropriate patients for this approach.
      (Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
    • References:
      Leukemia. 2009 Jun;23(6):1131-8. (PMID: 19194465)
      Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. (PMID: 25529383)
      Biol Blood Marrow Transplant. 2013 May;19(5):799-803. (PMID: 23416850)
      Blood. 1998 Feb 1;91(3):1083-90. (PMID: 9446672)
      Blood. 2013 Apr 11;121(15):2854-63. (PMID: 23355537)
      Biol Blood Marrow Transplant. 2012 May;18(5):690-7. (PMID: 21875505)
      Blood. 2007 Dec 15;110(13):4552-9. (PMID: 17717135)
      J Clin Oncol. 2014 Oct 10;32(29):3249-56. (PMID: 25154831)
      Biol Blood Marrow Transplant. 2011 Sep;17(9):1343-51. (PMID: 21320619)
      Biol Blood Marrow Transplant. 2013 Feb;19(2):208-13. (PMID: 22982534)
      Blood. 2007 Dec 15;110(13):4606-13. (PMID: 17873123)
      Blood. 2014 Jul 10;124(2):287-95. (PMID: 24797298)
      Blood. 2005 Oct 15;106(8):2912-9. (PMID: 15994282)
      J Clin Oncol. 2007 Sep 20;25(27):4246-54. (PMID: 17724349)
      Transplantation. 1985 Sep;40(3):317-22. (PMID: 3875918)
      Bone Marrow Transplant. 2015 Aug;50(8):1138-40. (PMID: 25985051)
      J Clin Oncol. 2012 Sep 10;30(26):3194-201. (PMID: 22869882)
      Bone Marrow Transplant. 2015 Nov;50(11):1405-10. (PMID: 26168067)
      Biol Blood Marrow Transplant. 2015 Dec;21(12 ):2106-14. (PMID: 26187863)
      Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. (PMID: 19922807)
      Blood. 2011 Mar 3;117(9):2728-34. (PMID: 21228326)
      Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92. (PMID: 18721761)
      Biol Blood Marrow Transplant. 2013 Jun;19(6):898-903. (PMID: 23467126)
      Bone Marrow Transplant. 2015 Apr;50(4):493-8. (PMID: 25621808)
      Biol Blood Marrow Transplant. 2008 Apr;14(4):458-68. (PMID: 18342789)
      Biol Blood Marrow Transplant. 2009 Feb;15(2):223-30. (PMID: 19167682)
    • Grant Information:
      P01 CA023766 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS
    • Contributed Indexing:
      Keywords: Allogeneic hematopoietic cell transplantation; Comorbidity; HCT-CI; T cell depletion
    • Accession Number:
      0 (Antigens, CD34)
    • Publication Date:
      Date Created: 20161030 Date Completed: 20180213 Latest Revision: 20181113
    • Publication Date:
      20231215
    • Accession Number:
      PMC5182101
    • Accession Number:
      10.1016/j.bbmt.2016.10.017
    • Accession Number:
      27789361